Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the ...

New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.

SELLAS Life Sciences reports successful Phase 2 trial results for SLS009 in relapsed/refractory AML, exceeding response and survival rates.

“Men with long life expectancy, even those with very high-risk cancer, were twice as likely to die of other causes than from prostate cancer. Our estimates of prostate cancer-specific and other-cause ...